



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	10/568,108
Filing Date	February 13, 2006
First Named Inventor	Alexandre Avrameas
Art Unit	1645
Examiner Name	Julie Ha

Sheet 1 of 5

Attorney Docket Number 62745.000020

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
/J.H./	1	US- 3,710,795	01-16-1973	Higuchi, et al.	
/J.H./	2	US- 5,262,564	11-16-1993	Kun, et al.	
/J.H./	3	US- 4,526,888	07-02-1985	Williams, et al.	
	4	US- 2004/0129948	06-24-2004	La Rosa, et al.	Duplicate, cited by Examiner
	5	US- 2007/0259015	11-08-2007	Aranz	Duplicate, cited by Examiner
/J.H./	6	US- 7,049,286	05-23-2006	Tchelingierian	
↓	7	US- 7,112,562	09-26-2006	Tchelingierian	
	8	US- 2003/0199677	10-23-2003	Avrameas, et al.	
↓	9	US- 2006/0281897	12-14-2006	Trouet, et al.	
/J.H./	10	US- 2007/0042492	02-22-2007	Avrameas	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

EXAMINER SIGNATURE /Julie Ha/

DATE CONSIDERED 04/21/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Application Number

10/568,108

Filing Date

February 13, 2006

First Named Inventor

Alexandre Avrameas

Art Unit

1645

Examiner Name

Julie Ha

Sheet

2 of 5

Attorney Docket Number

62745.000020

FOREIGN PATENT DOCUMENTS

[illegible]

EXAMINER SIGNATURE

/Julie Ha/

DATE CONSIDERED

04/21/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/568,108
		Filing Date	February 13, 2006
		First Named Inventor	Alexandre Avrameas
		Art Unit	1645
		Examiner Name	Julie Ha
Sheet	3 of 5	Attorney Docket Number	62745.000020

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
/J.H./	23	AVRAMEAS, "Efficient Gene Delivery by a Peptide Derived from a Monoclonal anti-DNA Antibody," Bioconjugate Chem., 1999, 10, pp. 87-93.	<input type="checkbox"/>	<input type="checkbox"/>
	24	BERNFELD, "Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans," Annu. Rev. Cell Biol., 8:365-393 (1992).	<input type="checkbox"/>	<input type="checkbox"/>
	25	BOSANQUET, "Chlorambucil: stability of solutions during preparation and storage," Cancer Chemother. Pharmacol., 18:176 (1986).	<input type="checkbox"/>	<input type="checkbox"/>
	26	CARDIN, "Molecular modeling of protein-glycosaminoglycan interactions," Arterioscler. Thromb. Vasc. Biol. 1989; 9; pp. 21-32.	<input type="checkbox"/>	<input type="checkbox"/>
	27	DARVEAU, "Beta-Lactam Antibiotics potentiate Magainin 2 Antimicrobial Activity In Vitro and In Vivo," Antimicrobial Agents and Chemotherapy, American Society for Microbiology, Vol. 35, No. 6, 1991, pp. 1153-1159.	<input type="checkbox"/>	<input type="checkbox"/>
	28	DAVID, "Integral membrane heparan sulfate proteoglycans," 7:1023, 1993.	<input type="checkbox"/>	<input type="checkbox"/>
	29	ESKO, "Animal cell mutants defective in glycosaminoglycan biosynthesis," Proc. Natl. Acad. Sci., Vol. 82, pp. 3197-3201, 1985.	<input type="checkbox"/>	<input type="checkbox"/>
	30	GUERITTE, "Relationships between the Structure of Taxol Analogues and Their Antimitotic Activity," J. Med. Chem., 34, 1991, pp. 992-996.	<input type="checkbox"/>	<input type="checkbox"/>
	31	MORROW, "Coordinated Action of Glutathione S-Transferases (GSTs) and Multidrug Resistance Protein 1 (MRP1) in Antineoplastic Drug Detoxification," J. Biol. Chem., Vol. 273, No. 32, pp. 20114-20120, 1998.	<input type="checkbox"/>	<input type="checkbox"/>
	32	NIIDOME, "Chain Length of Cationic alpha-Helical Peptide Sufficient for Gene Delivery into Cells," Bioconjugate Chemistry, Vol. 10, No. 5, 1999, pp. 773-780.	<input type="checkbox"/>	<input type="checkbox"/>
/J.H./	33	NOGALES, "A structure view of microtubule dynamics," Cell. Mol. Life Sci., Vol. 56, 1999, pp. 133-142.	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE /Julie Ha/	DATE CONSIDERED 04/21/2008
--------------------------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/568,108
		Filing Date	February 13, 2006
		First Named Inventor	Alexandre Avrameas
		Art Unit	1645
		Examiner Name	Julie Ha
Sheet	4 of 5	Attorney Docket Number	62745.000020

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
/J.H./	34	PARK, "Mechanism of Action of the Antimicrobial Peptide Bufen II: Bufen II Kills Microorganisms by Penetrating the Cell Membrane and Inhibiting Cellular Functions," Biochem. Biophys. Res. Commun., 244, pp. 253-257, 1998.	<input type="checkbox"/>	<input type="checkbox"/>
	35	ROSTAND, "Microbial Adherence to and Invasion Through Proteoglycans," Infection and Immunity, pp. 1-8, 1997.	<input type="checkbox"/>	<input type="checkbox"/>
	36	SILBER, "Chemosensitivity of Lymphocytes From Patients With B-Cell Chronic Lymphocytic Leukemia to Chlorambucil Fludarabine, and Camptothecin Analogs," Blood, 84:3440, 1994.	<input type="checkbox"/>	<input type="checkbox"/>
	37	TABOSA, "In-vitro and In-vivo evaluation of a new amphotericin B emulsion-based delivery system," J. Antimicrob. Chemother., 38, pp. 485-497, 1996.	<input type="checkbox"/>	<input type="checkbox"/>
	38	TRAVIS, "Risk of Leukemia Following Treatment for Non-Hodgkin's Lymphoma," J. Natl. Cancer Inst., 86:1450, 1994.	<input type="checkbox"/>	<input type="checkbox"/>
	39	WALL, "Camptothecin and Taxol: Discovery to Clinic - Thirteenth Bruce F. Cain Memorial Award Lecture," Cancer Res., 55:753, 1995.	<input type="checkbox"/>	<input type="checkbox"/>
	40	ZUNINO, "Molecular mechanisms of resistance to taxanes and therapeutic implications," Drug Resist. Updat., 2:351, 1999.	<input type="checkbox"/>	<input type="checkbox"/>
	41	International Search Report for International Application No. PCT/IB2004/002936. mailed October 2, 2005.	<input type="checkbox"/>	<input type="checkbox"/>
	42	French Search Report for French Patent Application No. FR0309962 mailed March 10, 2004.	<input type="checkbox"/>	<input type="checkbox"/>
	43	Partial European Search Report for European Patent Application No. EP 03292030 mailed March 1, 2004.	<input type="checkbox"/>	<input type="checkbox"/>
/J.H./	44	Written Opinion for International Application No. PCT/IB2004/002936.	<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE /Julie Ha/	DATE CONSIDERED 04/21/2008
--------------------------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Application Number	10/568,108
		Filing Date	February 13, 2006
		First Named Inventor	Alexandre Avrameas
		Art Unit	1645
		Examiner Name	Julie Ha
Sheet	5 of 5	Attorney Docket Number	62745.000020

OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS

*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	TRANSLATION	
			YES	NO
/J.H./	45	International Preliminary Report on Patentability for International Application No. PCT/IB2004/002936, issued February 21, 2006.	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>

EXAMINER SIGNATURE /Julie Ha/	DATE CONSIDERED 04/21/2008
--------------------------------------	-----------------------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.